Advanced Therapy Medicinal Products Market Size Projected to Reach $170 billion by 2034 | 16.5%

According to Straits Research, the global advanced therapy medicinal products (ATMP) market size was valued at $42 billion in 2025 and is projected to grow from $49 billion in 2026 to $170 billion by 2034, registering a CAGR of 16.5% during the forecast period 2026–2034.

Straits Research, a leading market research organization, announced the release of the report titled “Advanced Therapy Medicinal Products (ATMP) Market  Forecasts till 2034”. The report provides an in-depth analysis of the market size, trends, opportunities, and market mechanism. The report also covers a regional analysis of several market factors.

The Advanced Therapy Medicinal Products (ATMP) market is segmented based on therapy type, manufacturer, and region. Some of the insights provided in the report are highlighted below:

• The cell therapy segment is expected to register a CAGR of 16.5% during the forecast period.
• North America is expected to lead the market during the forecast period, owing to regulatory advantages and effective product launches by companies.
• Consumers worldwide are shifting toward regenerative medicine to reduce lifetime healthcare expenditure as well as minimize surgeries and long-term medication.
• Germany is expected to lead the Europe ATMP market due to early adoption of innovative therapies and a supportive reimbursement environment.

Straits Research adopts a rigorous 360° research approach that integrates both primary and secondary research methodologies. The report data is triangulated with a mix of market indicators, macroeconomic outlook, industry sources, and strategic briefings.

The report is designed to enable decision makers, such as CXOs, policymakers, investors, startups, and other related stakeholders, to understand the current and future scenario of the market.

North America dominated the Advanced Therapy Medicinal Products (ATMP) market with the largest share of 51% in 2025. The region has robust regulatory pathways and advanced manufacturing infrastructure. It also hosts major viral vector facilities, cell therapy production sites, and leading CDMOs (e.g., Lonza US operations, Thermo Fisher, and Catalent). The region boasts a strong clinical trial ecosystem, world-class academic research institutions, and leading cancer and rare disease centers.

The Asia Pacific is expected to be the fastest-growing region in the market during the forecast period. This growth is attributed to the growing healthcare demand and rising investments directed toward biotech and regenerative medicine. A surge in biotech funding and government support for biotech parks, manufacturing hubs, and innovation grants supports the regional development of advanced therapy medicinal products.

Market Segments

1. By Therapy Type
   1. Cell Therapy
   2. Gene Therapy
   3. CAR-T Therapy
   4. Tissue Engineered Products
2. By Manufacturer
   1. Biopharmaceutical Companies
   2. Contract Development and Manufacturing Organizations (CDMOs)
   3. Digital Platform Providers
3. By Region
   1. North America
   2. Europe
   3. Asia Pacific
   4. Middle East and Africa
   5. Latin America